Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

REFILE-Novavax COVID-19 vaccine could be approved very soon, says EMA chief

12/07/2021 | 09:02am EST

BRUSSELS, Dec 7 (Reuters) - The head of the European Medicines Agency (EMA) on Tuesday said that it could soon approve the COVID-19 vaccine developed by U.S. biotech company Novavax.

"The vaccine from Novavax could be authorised in the very near future," Emer Cooke told EU health ministers during a public session of a meeting in Brussels. (Reporting by Francesco Guarascio Editing by David Goodman)


ę Reuters 2021
All news about NOVAVAX, INC.
01/21Cowen Starts Novavax at Outperform With $150 Price Target
MT
01/20Global markets live: Unilever, United Airlines, Amazon, Walt Disney, Novavax...
01/20WALL STREET STOCK EXCHANGE : Nasdaq aims for rebound after entering correction territory
01/20Health Care Stocks Advance Premarket Thursday
MT
01/20Bill & Melinda Gates Foundation and Wellcome Pledge U.S.$300 Million to CEPI for Covid-..
AQ
01/20Novavax Obtains Approval for Provisional Registration of COVID-19 Vaccine in Australia
MT
01/20Australia says no to 16-year-old forklift drivers as remedy to COVID supply chain pain
RE
01/19Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for No..
PR
01/19Valneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
DJ
01/18Gates, Wellcome pledge $150 mln each to pandemic preparedness group
RE
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2021 1 378 M - -
Net income 2021 -919 M - -
Net cash 2021 756 M - -
P/E ratio 2021 -6,88x
Yield 2021 -
Capitalization 6 400 M 6 400 M -
EV / Sales 2021 4,10x
EV / Sales 2022 1,10x
Nbr of Employees 792
Free-Float -
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 84,65 $
Average target price 270,00 $
Spread / Average Target 219%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-40.83%6 400
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508